111 related articles for article (PubMed ID: 34659195)
1. Expansion of Human Papillomavirus-Specific T Cells in Periphery and Cervix in a Therapeutic Vaccine Recipient Whose Cervical High-Grade Squamous Intraepithelial Lesion Regressed.
Shibata T; Shah S; Evans T; Coleman H; Lieblong BJ; Spencer HJ; Quick CM; Sasagawa T; Stephens OW; Peterson E; Johann D; Lu YC; Nakagawa M
Front Immunol; 2021; 12():645299. PubMed ID: 34659195
[TBL] [Abstract][Full Text] [Related]
2. Cervical Microbiome and Response to a Human Papillomavirus Therapeutic Vaccine for Treating High-Grade Cervical Squamous Intraepithelial Lesion.
Ravilla R; Coleman HN; Chow CE; Chan L; Fuhrman BJ; Greenfield WW; Robeson MS; Iverson K; Spencer H; Nakagawa M
Integr Cancer Ther; 2019; 18():1534735419893063. PubMed ID: 31833799
[TBL] [Abstract][Full Text] [Related]
3. Human Papillomavirus T-Cell Cross-reactivity in Cervical Cancer: Implications for Immunotherapy Clinical Trial Design.
Helman SR; Stevanovic S; Campbell TE; Kwong MLM; Doran SL; Faquin WC; Hinrichs CS
JAMA Netw Open; 2018 Jul; 1(3):e180706. PubMed ID: 30646017
[TBL] [Abstract][Full Text] [Related]
4. Human papillomavirus type 16 (HPV-16) virus-like particle L1-specific CD8+ cytotoxic T lymphocytes (CTLs) are equally effective as E7-specific CD8+ CTLs in killing autologous HPV-16-positive tumor cells in cervical cancer patients: implications for L1 dendritic cell-based therapeutic vaccines.
Bellone S; El-Sahwi K; Cocco E; Casagrande F; Cargnelutti M; Palmieri M; Bignotti E; Romani C; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
J Virol; 2009 Jul; 83(13):6779-89. PubMed ID: 19386711
[TBL] [Abstract][Full Text] [Related]
5. Local applications of GM-CSF induce the recruitment of immune cells in cervical low-grade squamous intraepithelial lesions.
Hubert P; Doyen J; Capelle X; Arafa M; Renoux V; Bisig B; Seidel L; Evrard B; Bousarghin L; Gerday C; Boniver J; Foidart JM; Delvenne P; Jacobs N
Am J Reprod Immunol; 2010 Aug; 64(2):126-36. PubMed ID: 20367631
[TBL] [Abstract][Full Text] [Related]
6. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia.
Kenter GG; Welters MJ; Valentijn AR; Lowik MJ; Berends-van der Meer DM; Vloon AP; Essahsah F; Fathers LM; Offringa R; Drijfhout JW; Wafelman AR; Oostendorp J; Fleuren GJ; van der Burg SH; Melief CJ
N Engl J Med; 2009 Nov; 361(19):1838-47. PubMed ID: 19890126
[TBL] [Abstract][Full Text] [Related]
7. Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicity.
Kenter GG; Welters MJ; Valentijn AR; Lowik MJ; Berends-van der Meer DM; Vloon AP; Drijfhout JW; Wafelman AR; Oostendorp J; Fleuren GJ; Offringa R; van der Burg SH; Melief CJ
Clin Cancer Res; 2008 Jan; 14(1):169-77. PubMed ID: 18172268
[TBL] [Abstract][Full Text] [Related]
8. Success or failure of vaccination for HPV16-positive vulvar lesions correlates with kinetics and phenotype of induced T-cell responses.
Welters MJ; Kenter GG; de Vos van Steenwijk PJ; Löwik MJ; Berends-van der Meer DM; Essahsah F; Stynenbosch LF; Vloon AP; Ramwadhdoebe TH; Piersma SJ; van der Hulst JM; Valentijn AR; Fathers LM; Drijfhout JW; Franken KL; Oostendorp J; Fleuren GJ; Melief CJ; van der Burg SH
Proc Natl Acad Sci U S A; 2010 Jun; 107(26):11895-9. PubMed ID: 20547850
[TBL] [Abstract][Full Text] [Related]
9. Pembrolizumab plus GX-188E therapeutic DNA vaccine in patients with HPV-16-positive or HPV-18-positive advanced cervical cancer: interim results of a single-arm, phase 2 trial.
Youn JW; Hur SY; Woo JW; Kim YM; Lim MC; Park SY; Seo SS; No JH; Kim BG; Lee JK; Shin SJ; Kim K; Chaney MF; Choi YJ; Suh YS; Park JS; Sung YC
Lancet Oncol; 2020 Dec; 21(12):1653-1660. PubMed ID: 33271094
[TBL] [Abstract][Full Text] [Related]
10. Increased Response of Human T-Lymphocytes by Dendritic Cells Pulsed with HPV16E7 and Pleurotus sajor-caju-β-glucan (PBG).
Roopngam PE
Iran J Immunol; 2018 Dec; 15(4):246-255. PubMed ID: 30593739
[TBL] [Abstract][Full Text] [Related]
11. Human papillomavirus 16-specific T-cell responses and spontaneous regression of anal high-grade squamous intraepithelial lesions.
Tong WW; Shepherd K; Garland S; Meagher A; Templeton DJ; Fairley CK; Jin F; Poynten IM; Zaunders J; Hillman RJ; Grulich AE; Kelleher AD; Carr A;
J Infect Dis; 2015 Feb; 211(3):405-15. PubMed ID: 25139018
[TBL] [Abstract][Full Text] [Related]
12. Prevention and treatment of cervical cancer by a single administration of human papillomavirus peptide vaccine with CpG oligodeoxynucleotides as an adjuvant in vivo.
Yang Y; Che Y; Zhao Y; Wang X
Int Immunopharmacol; 2019 Apr; 69():279-288. PubMed ID: 30743204
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapy in patients with local HPV infection and high-grade squamous intraepithelial lesion following uterine cervical conization.
Kovachev SM
Immunopharmacol Immunotoxicol; 2020 Aug; 42(4):314-318. PubMed ID: 32429720
[TBL] [Abstract][Full Text] [Related]
14. A review of cross-protection against oncogenic HPV by an HPV-16/18 AS04-adjuvanted cervical cancer vaccine: importance of virological and clinical endpoints and implications for mass vaccination in cervical cancer prevention.
Jenkins D
Gynecol Oncol; 2008 Sep; 110(3 Suppl 1):S18-25. PubMed ID: 18653221
[TBL] [Abstract][Full Text] [Related]
15. An unexpectedly large polyclonal repertoire of HPV-specific T cells is poised for action in patients with cervical cancer.
de Vos van Steenwijk PJ; Heusinkveld M; Ramwadhdoebe TH; Löwik MJ; van der Hulst JM; Goedemans R; Piersma SJ; Kenter GG; van der Burg SH
Cancer Res; 2010 Apr; 70(7):2707-17. PubMed ID: 20233872
[TBL] [Abstract][Full Text] [Related]
16. Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine.
Welters MJ; Kenter GG; Piersma SJ; Vloon AP; Löwik MJ; Berends-van der Meer DM; Drijfhout JW; Valentijn AR; Wafelman AR; Oostendorp J; Fleuren GJ; Offringa R; Melief CJ; van der Burg SH
Clin Cancer Res; 2008 Jan; 14(1):178-87. PubMed ID: 18172269
[TBL] [Abstract][Full Text] [Related]
17. Vaccination Against Human Papilloma Viruses Leads to a Favorable Cytokine Profile of Specific T Cells.
Luckau S; Wehrs TP; Brandau S; Horn PA; Lindemann M
J Immunother; 2016 Oct; 39(8):316-20. PubMed ID: 27548034
[TBL] [Abstract][Full Text] [Related]
18. A phase I trial of a human papillomavirus DNA vaccine for HPV16+ cervical intraepithelial neoplasia 2/3.
Trimble CL; Peng S; Kos F; Gravitt P; Viscidi R; Sugar E; Pardoll D; Wu TC
Clin Cancer Res; 2009 Jan; 15(1):361-7. PubMed ID: 19118066
[TBL] [Abstract][Full Text] [Related]
19. Effect of Progestin Usage on the Interpretation of Cervical High-grade Squamous Intraepithelial Lesion.
Wang Y; Chen H; Jiang Q; Luo R; Zhou P; Wang Y; Zhao R; Fadare O; Zheng W
Am J Surg Pathol; 2019 Aug; 43(8):1066-1073. PubMed ID: 31045892
[TBL] [Abstract][Full Text] [Related]
20. Human papillomavirus type 16 viral load is decreased following a therapeutic vaccination.
Coleman HN; Greenfield WW; Stratton SL; Vaughn R; Kieber A; Moerman-Herzog AM; Spencer HJ; Hitt WC; Quick CM; Hutchins LF; Mackintosh SG; Edmondson RD; Erickson SW; Nakagawa M
Cancer Immunol Immunother; 2016 May; 65(5):563-73. PubMed ID: 26980480
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
